A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB).
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Vatalanib (Primary)
- Indications CNS cancer; Haemangioblastoma
- Focus Biomarker; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 Feb 2011 Actual end date (June 2006) added as reported by ClinicalTrials.gov.
- 01 Oct 2009 New trial record